Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Caelyx recommended as treatment of ovarian cancer in U.K.
June 30th, 2005
The United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued its final guidance recommending the use of Caelyx (pegylated liposomal doxorubicin hydrochloride) as an option for the second-line treatment or subsequent treatment of women with advanced ovarian cancer. This recommendation includes the treatment of women with partially platinum-sensitive, platinum-resistant, or platinum-refractory advanced ovarian cancer, and for women who are allergic to platinum-based compounds. Partially platinum-sensitive ovarian cancer delineates tumor that relapses between 6 and 12 months following initial platinum-based chemotherapy;...
Source: Women's Health Weekly (2005-06-30)
|
